Cleo Diagnostics (ASX:COV) Selling, General, & Admin. Expense : A$ Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Cleo Diagnostics's selling, general, & admin. expense for the six months ended in Dec. 2023 was A$0.52 Mil. Cleo Diagnostics does not have enough years/quarters to calculate its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2023.

Cleo Diagnostics Selling, General, & Admin. Expense Historical Data

The historical data trend for Cleo Diagnostics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Selling, General, & Admin. Expense Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Selling, General, & Admin. Expense

1.10

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Selling, General, & Admin. Expense	0.23	0.86	0.52

Competitive Comparison of Cleo Diagnostics's Selling, General, & Admin. Expense

For the Medical Devices subindustry, Cleo Diagnostics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics's Selling, General, & Admin. Expense Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Selling, General, & Admin. Expense falls into.

Cleo Diagnostics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Cleo Diagnostics (ASX:COV) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.

Cleo Diagnostics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Selling, General, & Admin. Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines